Simultaneous Pancreas–Kidney Versus Kidney Transplant Alone: Real-World Outcomes in a Propensity-Matched Global Cohort

Abstract

The true comparative effectiveness of simultaneous pancreas–kidney transplantation (SPKT) versus kidney transplantation alone (KTA) in patients with diabetes and end-stage renal disease remains incompletely defined. Using the TriNetX Global Collaborative Network (2010–2024), we identified 3,679 SPKT and 27,062 KTA recipients aged 18–59 years. In unmatched comparisons, SPKT recipients showed lower mortality, fewer cardiovascular events, and improved kidney graft survival relative to KTA recipients, but also higher early rejection, infection, and readmission rates. After 1:1 propensity score matching, long-term estimates for survival (HR 1.00, 95% CI 0.90–1.10), kidney graft failure (HR 0.99, 95% CI 0.94–1.04), and cardiovascular events (HR 0.99, 95% CI 0.94–1.05) no longer differed over 10 years. In contrast, SPKT recipients maintained significantly lower HbA1c levels throughout follow-up (mean 6.2% vs 6.6% at 5 years; p<0.001). Sensitivity analyses restricted to type 1 diabetes and non-obese recipients yielded consistent results. After accounting for measured differences between recipients, we did not detect a long-term survival advantage of SPKT over KTA, whereas durable metabolic benefits persisted. Because key donor and immunologic characteristics were not available, a modest intrinsic survival benefit cannot be excluded. These findings highlight the major role of patient selection and support individualised use of SPKT